BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 1, 2011, Pages 92-99

  King Jr , Talmadge E ^a   Brown, Kevin K ^b   Raghu, Ganesh ^c   Du Bois, Roland M ^d   Lynch, David A ^b   Martinez, Fernando ^e   Valeyre, Dominique ^f   Leconte, Isabelle ^g   Morganti, Adele ^g   Roux, Sébastien ^g   Behr, Juergen ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f AVICENNE HOSPITAL   (France)

^g ACTELION PHARMACEUTICALS LTD   (Switzerland)

^h RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Clinical trial; Endothelin receptor antagonism; High resolution computed tomography; Pulmonary function tests; Surgical lung biopsy

Indexed keywords

BOSENTAN; CARBON MONOXIDE; PLACEBO;

ADULT; AGED; ARTICLE; BRONCHITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; HEADACHE; HUMAN; LUNG BIOPSY; LUNG CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; QUALITY OF LIFE; SULFONAMIDES; SURVIVAL RATE; VITAL CAPACITY;

EID: 80051566676     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201011-1874OC     Document Type: Article

References (31)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
2. American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
3. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816. (Pubitemid 44511663)
4. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203. (Pubitemid 28071283)
5. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-1181. (Pubitemid 33052246)
6. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537. (Pubitemid 37088594)
7. Selman M, King TE, Pardo A; American Thoracic Society. European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151. (Pubitemid 32096342)
8. Ross B, D'Orléans-Juste P, Giaid A. Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am J Respir Cell Mol Biol 2010;42:16-20.
9. Park S-H, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:600-608. (Pubitemid 27352001)
10. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
11. Raghu G, King TE Jr, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, Swigris J. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010;35:118-123.
12. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez FJ, Valeyre D, Leconte I, Morganti A, Roux S, et al. The BUILD-3 trial: a prospective, randomized, double-blind, placebo-controlled study of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:A6838. (abstract).
13. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's Manual for the SF-36v2TM Health Survey, 2nd ed. Lincoln, RI: QualityMetric Incorporated; 2007.
14. EuroQoL Group. EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
15. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758. (Pubitemid 14121920)
16. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
17. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-344. (Pubitemid 47194187)
18. Galiè N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-2100. (Pubitemid 351902178)
19. Noble P, Albera C, Bradford W, Costabel U, Kardatzke D, King TE Jr, Sahn S, Szwarcberg J, Valeyre D, du Bois RM. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) [abstract]. Am J Respir Crit Care Med 2009;179:A1129.
20. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-228.
21. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542. (Pubitemid 37088595)
22. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132:1652-1658. (Pubitemid 350156025)
23. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-955.
24. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-829.
25. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, et al IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-967.
26. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr; Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133. (Pubitemid 38056223)
27. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-2242. (Pubitemid 41697286)
28. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-836.
29. du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Raghu G, Szwarcberg J, Thomeer M, Valeyre D, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis (IPF) [abstract]. Am J Respir Crit Care Med 2010;181:A2499.
30. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-548. (Pubitemid 37088596)
31. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-177. (Pubitemid 41724573)